Table 4.
Treatment toxicity in patients treated with 6 or 12 cycles of temozolomide.
| Adverse event | 6-cycle group 45 patients N (%) |
12-Cycle group 49 patients N (%) |
||||||
|---|---|---|---|---|---|---|---|---|
| Grade 1 |
Grade 2 | Grade 3 | Grade 4 | Grade 1 |
Grade 2 | Grade 3 | Grade 4 |
|
| Neutropenia | 39 (84.8) |
5 (10.9) | 2 (4.3) |
0 | 46 (95.8) |
2 (4.2) |
0 | 0 |
| Thrombocytopenia | 39 (84.8) |
4 (8.7) |
2 (4.3) |
1 | 44 (91.7) |
4 (8.3) |
0 | 0 |
| Anemia | 44 (95.7) |
2 (4.3) |
0 | 0 | 47 (97.9) |
1 (2.1) |
0 | 0 |
| Nausea/vomiting | 36 (87.2) |
3 (6.6) |
0 | 0 | 45 (95.7) |
2 (4.2) |
0 | 0 |